News

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...
LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong ...
We’re aiming to raise $17,000 by August 10, so we can deepen our reporting on the critical stories unfolding right ...
Genethon gets UK MHRA nod to initiate pivotal phase 3 trial of GNT0004, a low-dose microdystrophin gene therapy for Duchenne muscular dystrophy: Paris, France Wednesday, July 30, ...
A Delta doctor who's at the forefront of organ transplant medicine in B.C. is the recipient of this year's Clinic Trials BC ...
Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the ...
The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.
The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 ...
LENZ Therapeutics' LNZ100 leads presbyopia treatment with superior efficacy and FDA approval likely by Aug. 2025. Learn more ...
Novocure's Tumor Treating Fields tech offers promise in oncology. NVCR trades at a compelling valuation after the recent ...
Total joint replacements have transformed millions of lives, but their success demands rigorous assessment of long-term safety, durability, and performance.